Dear patients, shareholders, friends,
In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019.
Recent Posts
SCENESSE® registration dossier submitted in Australia
CLINUVEL initiates the registration process under priority review for its new pharmaceutical...
Read More
Notice of Change of Interests of Substantial Holder
Form 604 – Notice of change of interests of substantial holder...
Read More